Rash News and Research

RSS

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).

3 Nov 2015

Loyola pediatrician reveals signs and symptoms of childhood rashes

Sniffles, stomach bugs, fever and sore throats are often associated with viruses, but rashes are common in children with viral infections as well.

30 Oct 2015

Yervoy approved for patients at high risk of developing recurrence of melanoma after surgery

Today the U.S. Food and Drug Administration expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery.

29 Oct 2015

Infections with Lone star ticks appear to be surging but deaths are not, new study reveals

A mild disease spread by the aggressive Lone star tick that is now colonizing large swaths of the United States is being mistaken for Rocky Mountain spotted fever, according to a new study from scientists at the U.S. Centers for Disease Control and Prevention.

28 Oct 2015

Early trial results in lung cancer

Results from early phase trials investigating different therapeutic agents in lung cancer patients were presented during the third Presidential Session at the European Cancer Congress in Vienna, Austria. Here we summarise two studies reported at the session.

22 Oct 2015

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP). Promacta can be used in these children when they have not achieved an appropriate response using other ITP medicines or surgery to remove the spleen.

9 Oct 2015

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar (glucose) control in adults with diabetes mellitus.

9 Oct 2015

Repatha (evolocumab) injection gets FDA approval for high cholesterol

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options.

9 Oct 2015

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.

9 Oct 2015

NS1 protein can be considered as vital target for development of new drugs to treat dengue: Study

Dengue is a mosquito-borne tropical disease currently endemic in more than 10 countries. According to the World Health Organization, 390 million people are infected by dengue every year.

7 Oct 2015

Skin rashes and fever in adults could signal life-threatening conditions

Adults with skin rashes accompanied by a fever of 100.5 or higher warrant a trip to the emergency room because the combination of symptoms can be associated with several life-threatening conditions, according to the American College of Osteopathic Emergency Physicians.

6 Oct 2015

Osteopathic physicians, researchers to present clinical and research updates at OMED 15

Osteopathic physicians, researchers and aligned medical professionals will present clinical and research updates in 15 specialties at OMED 15 in Orlando October 17-21.

6 Oct 2015

Paradigm failure is primary reason for lack of progress in cancer research, says cancer biologist

A recent publication, which received sustained media attention, claimed that most cancers are just “bad luck”. Its authors stated that only about one-third of cancer mutations are caused by known lifestyle or environmental factors.

6 Oct 2015

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung

29 Sep 2015

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.

28 Sep 2015

Results from phase 3 women-only HIV study show improved safety, efficacy of Stribild drug

Results from the first phase 3 HIV study to enroll only women show improved safety and efficacy of the drug Stribild over multi-pill antiretroviral drug regimens. The research was presented at ASM's 55th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC/ICC).

21 Sep 2015

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy.

26 Aug 2015

Caring for young children with eczema

The excitement of a newborn baby turned to worry when a few weeks after Lorenzo Torres-Ramirez was born his parents started to notice red spots on his face.

21 Aug 2015

Study reports results of genetic testing for 22 genetic causes of neonatal diabetes

Over a 10 year period, the time that babies receive genetic testing after being diagnosed with diabetes has fallen from over four years to under two months. Pinpointing the exact genetic causes of sometimes rare forms of diabetes is revolutionising healthcare for these patients.

18 Aug 2015

NanoViricides speeds up HerpeCide drug development program

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, reports that it is accelerating its HerpeCide drug development program.

17 Aug 2015

Rash News and Research

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Loyola pediatrician reveals signs and symptoms of childhood rashes

Yervoy approved for patients at high risk of developing recurrence of melanoma after surgery

Infections with Lone star ticks appear to be surging but deaths are not, new study reveals

Early trial results in lung cancer

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

Repatha (evolocumab) injection gets FDA approval for high cholesterol

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

NS1 protein can be considered as vital target for development of new drugs to treat dengue: Study

Skin rashes and fever in adults could signal life-threatening conditions

Osteopathic physicians, researchers to present clinical and research updates at OMED 15

Paradigm failure is primary reason for lack of progress in cancer research, says cancer biologist

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Results from phase 3 women-only HIV study show improved safety, efficacy of Stribild drug

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Caring for young children with eczema

Study reports results of genetic testing for 22 genetic causes of neonatal diabetes

NanoViricides speeds up HerpeCide drug development program

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News